Diabetes is an enormous health burden worldwide, and the current epidemic of type 2 diabetes is of paramount concern. The most important recent advances in the management of type 1 diabetes have been immunotherapies, designed to delay disease onset and the development of fully automated artificial pancreas systems that integrate blood glucose monitoring and insulin delivery. In type 2 diabetes, the widespread use of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors have facilitated optimal glycaemic control without increased risk of hypoglycaemia and weight gain. Emerging data from cardiovascular outcome trials have shown that these agents can reduce the risk of cardiovascular disease in high-risk individuals.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
We are pleased to present the latest issue of touchREVIEWS in Endocrinology, which offers a timely and thoughtprovoking collection of articles that reflect both the continuity and evolution of diabetes and metabolic disease research. In an era where technology, public ...
Watch multidisciplinary speakers discuss optimising AID outcomes and individualising AID education to support children with type 1 diabetes.
In this insightful interview, Dr Veronica J. Brady, 2025 President of the Association of Diabetes Care & Education Specialists (ADCES), speaks about the organization’s mission to empower diabetes care and education specialists and improve patient outcomes. Dr Brady discusses the ...
A multidisciplinary team and a patient advocate discuss best practices for insulin therapy in T2D
Coronavirus disease 2019 (COVID-19) is a life-threatening infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1Â Diabetes mellitus is one of the most frequent comorbidities, related to hospitalization due to SARS-CoV-2 infection, as well as a risk factor for disease severity, ...
As we continue advancing the field of endocrinology, I’m excited to spotlight the impactful work being done by the American Association of Clinical Endocrinology (AACE). Our mission is to elevate the practice of clinical endocrinology to improve global health. ...
ATTD 2025 showcased 36 startups revolutionizing diabetes care with innovations like non-invasive monitoring, AI diagnostics, and real-time health tools. Awarded grants highlighted ATTD’s commitment to advancing personalized, tech-driven solutions that empower patients and transform global diabetes management.
The 17th ATTD Conference (Amsterdam, 19–22 March 2025) showcased major innovations in diabetes care. The 15-day Dexcom G7 CGM proved accurate and user-friendly. The RADIANT trial showed Omnipod® 5 significantly improved glucose control over injections in type 1 diabetes. In type 2 diabetes, the 2IQP Study highlighted benefits of AID systems. Teplizumab also showed potential to enhance glycaemic stability in newly diagnosed type 1 diabetes, reinforcing the role of technology and immunotherapy in advancing diabetes management.
Women & Diabetes takes centre stage in this interview with Zeina Abou Rizk, Founder of DiaLeb. Zeina explores the unique challenges women face in diabetes care, the power of community and advocacy, and how DiaLeb’s annual panel fosters global awareness, education, and meaningful change through lived experiences and expert insights.
Dr Linda Siminerio, a leading expert in diabetes education and healthcare delivery, shares insights from her distinguished career. Inspired by her father’s type 1 diabetes diagnosis, she has dedicated her work to improving patient education and care models. She emphasizes the importance of a team-based approach and staying ahead of technological advancements. With AI and machine learning already influencing diabetes management, she urges healthcare providers to adapt and engage with these innovations. Through her contributions, Dr Siminerio continues to shape the future of diabetes care, ensuring that patients receive the education and support they need.
Diabetes is a chronic disease associated with both acute and chronic complications. Many advances have been introduced throughout history to address these problems. While each clinical breakthrough was welcomed with relief and the expectation that a solution had been discovered, ...
The potential future role of GLP-1–based combinations in the management of obesity with or without diabetes.
Article Highlights Early use of sodium–glucose co-transporter-2 inhibitors following myocardial infarction was associated with the following factors: Lower hospitalization for heart failure (odds ratio [OR]: 0.75; 95% confidence interval [CI]: 0.62–0.90; p=0.002). Similar cardiovascular deaths (OR: 1.04; 95% CI: 0.83–1.30; p=0.76). Similar all-cause mortality (OR: 1.00; 95% ...
The 3-year results from the SURMOUNT-1 trial, published in the New England Journal of Medicine, have revealed that tirzepatide significantly reduced the risk of progression to type 2 diabetes (T2D) in individuals with obesity and prediabetes. T2D onset was ...
In 2025, the International Diabetes Federation (IDF) will host its World Diabetes Congress in Bangkok, Thailand, from 7-10 April. It will be my immense pleasure to welcome you there as President of the International Diabetes Federation, along with a new Board ...
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.